# PFM Health Sciences, LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1442756. Source: https://holderbook.com/funds/1442756-pfm-health-sciences-lp/

- Reported value: $1.2B
- Positions: 96
- Weight of the ten largest: 33.9%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $62.2M | 233,171 | 5.3% | 1 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $53.8M | 219,596 | 4.6% | 17 |
| ELI LILLY & CO | [LLY](https://holderbook.com/stocks/LLY/) | $47.1M | 39,258 | 4.0% | 23 |
| JAZZ PHARMACEUTICALS PLC | [JAZZ](https://holderbook.com/stocks/JAZZ/) | $38.7M | 160,768 | 3.3% | 3 |
| HUMANA INC | [HUM](https://holderbook.com/stocks/HUM/) | $37.5M | 94,375 | 3.2% | 1 |
| UNITEDHEALTH GROUP INC | [UNH](https://holderbook.com/stocks/UNH/) | $36.7M | 88,276 | 3.1% | 3 |
| NEUROCRINE BIOSCIENCES INC | [NBIX](https://holderbook.com/stocks/NBIX/) | $36.0M | 213,407 | 3.1% | 5 |
| INHIBRX BIOSCIENCES INC | [INBX](https://holderbook.com/stocks/INBX/) | $29.2M | 308,385 | 2.5% | 9 |
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $27.1M | 49,991 | 2.3% | 5 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $26.8M | 143,222 | 2.3% | 4 |
| ICON PUB LTD CO | [ICLR](https://holderbook.com/stocks/ICLR/) | $23.7M | 136,482 | 2.0% | 29 |
| TENET HEALTHCARE CORP | [THC](https://holderbook.com/stocks/THC/) | $23.7M | 126,572 | 2.0% | 25 |
| EDWARDS LIFESCIENCES CORP | [EW](https://holderbook.com/stocks/EW/) | $22.7M | 250,453 | 1.9% | 31 |
| WATERS CORP | [WAT](https://holderbook.com/stocks/WAT/) | $22.4M | 59,825 | 1.9% | 10 |
| CENTENE CORP DEL | [CNC](https://holderbook.com/stocks/CNC/) | $21.6M | 248,867 | 1.9% | 4 |
| PENUMBRA INC | [PEN](https://holderbook.com/stocks/PEN/) | $19.0M | 60,221 | 1.6% | 31 |
| BRIDGEBIO PHARMA INC | [BBIO](https://holderbook.com/stocks/BBIO/) | $18.9M | 253,358 | 1.6% | 7 |
| STRYKER CORPORATION | [SYK](https://holderbook.com/stocks/SYK/) | $17.8M | 56,637 | 1.5% | 3 |
| METTLER TOLEDO INTERNATIONAL | [MTD](https://holderbook.com/stocks/MTD/) | $17.0M | 13,344 | 1.5% | 1 |
| INDIVIOR PHARMACEUTICALS INC | [INDV](https://holderbook.com/stocks/INDV/) | $16.5M | 401,208 | 1.4% | 2 |
| MERCK & CO INC | [MRK](https://holderbook.com/stocks/MRK/) | $16.3M | 127,118 | 1.4% | 1 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $16.3M | 191,686 | 1.4% | 1 |
| LANTHEUS HLDGS INC | [LNTH](https://holderbook.com/stocks/LNTH/) | $16.2M | 146,403 | 1.4% | 1 |
| COOPER COS INC | [COO](https://holderbook.com/stocks/COO/) | $15.8M | 220,890 | 1.4% | 4 |
| MADRIGAL PHARMACEUTICALS INC | [MDGL](https://holderbook.com/stocks/MDGL/) | $15.7M | 29,313 | 1.4% | 3 |
| ACADIA HEALTHCARE COMPANY IN | [ACHC](https://holderbook.com/stocks/ACHC/) | $15.5M | 524,934 | 1.3% | 2 |
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $15.1M | 158,825 | 1.3% | 2 |
| OSCAR HEALTH INC | [OSCR](https://holderbook.com/stocks/OSCR/) | $14.8M | 519,016 | 1.3% | 13 |
| THERMO FISHER SCIENTIFIC INC | [TMO](https://holderbook.com/stocks/TMO/) | $14.3M | 28,496 | 1.2% | 4 |
| CVS HEALTH CORP | [CVS](https://holderbook.com/stocks/CVS/) | $14.2M | 137,457 | 1.2% | 1 |
| MERIT MED SYS INC | [MMSI](https://holderbook.com/stocks/MMSI/) | $13.7M | 197,038 | 1.2% | 2 |
| PRAXIS PRECISION MEDICINES I | [PRAX](https://holderbook.com/stocks/PRAX/) | $12.9M | 38,575 | 1.1% | 11 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $12.8M | 342,751 | 1.1% | 3 |
| NOVO-NORDISK A S | [NVO](https://holderbook.com/stocks/NVO/) | $12.7M | 265,016 | 1.1% | 2 |
| INTEGER HLDGS CORP | [ITGR](https://holderbook.com/stocks/ITGR/) | $11.8M | 126,669 | 1.0% | 3 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $11.8M | 121,222 | 1.0% | 4 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $11.7M | 249,020 | 1.0% | 2 |
| GILEAD SCIENCES INC | [GILD](https://holderbook.com/stocks/GILD/) | $11.5M | 90,858 | 1.0% | 1 |
| RHYTHM PHARMACEUTICALS INC | [RYTM](https://holderbook.com/stocks/RYTM/) | $11.3M | 101,550 | 1.0% | 4 |
| SCHEIN HENRY INC | [HSIC](https://holderbook.com/stocks/HSIC/) | $11.2M | 134,423 | 1.0% | 2 |
| ARROWHEAD PHARMACEUTICALS IN | [ARWR](https://holderbook.com/stocks/ARWR/) | $10.7M | 131,667 | 0.9% | 2 |
| TANGO THERAPEUTICS INC | [TNGX](https://holderbook.com/stocks/TNGX/) | $10.2M | 326,047 | 0.9% | 2 |
| TELEFLEX INCORPORATED | [TFX](https://holderbook.com/stocks/TFX/) | $10.1M | 79,708 | 0.9% | 1 |
| CENCORA INC | [COR](https://holderbook.com/stocks/COR/) | $10.0M | 7,385 | 0.9% | 1 |
| VIKING THERAPEUTICS INC | [VKTX](https://holderbook.com/stocks/VKTX/) | $10.0M | 255,330 | 0.9% | 5 |
| BRIGHTSPRING HEALTH SVCS INC | [BTSG](https://holderbook.com/stocks/BTSG/) | $9.9M | 141,914 | 0.8% | 3 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $9.6M | 224,289 | 0.8% | 4 |
| ROIVANT SCIENCES LTD | [ROIV](https://holderbook.com/stocks/ROIV/) | $9.5M | 268,008 | 0.8% | 2 |
| CG ONCOLOGY INC | [CGON](https://holderbook.com/stocks/CGON/) | $9.1M | 128,286 | 0.8% | 4 |
| AMNEAL PHARMACEUTICALS INC | [AMRX](https://holderbook.com/stocks/AMRX/) | $8.3M | 480,715 | 0.7% | 4 |
| EUPRAXIA PHARMACEUTICALS INC | [EPRX](https://holderbook.com/stocks/EPRX/) | $8.0M | 1,210,661 | 0.7% | 2 |
| IRHYTHM HOLDINGS INC | [IRTC](https://holderbook.com/stocks/IRTC/) | $7.8M | 65,196 | 0.7% | 1 |
| KODIAK SCIENCES INC | [KOD](https://holderbook.com/stocks/KOD/) | $7.5M | 193,315 | 0.6% | 2 |
| ABBOTT LABORATORIES | [ABT](https://holderbook.com/stocks/ABT/) | $7.5M | 82,230 | 0.6% | 2 |
| WEST PHARMACEUTICAL SVSC INC | [WST](https://holderbook.com/stocks/WST/) | $7.4M | 20,733 | 0.6% | 1 |
| TAKEDA PHARMACEUTICAL CO LTD | [TAK](https://holderbook.com/stocks/TAK/) | $7.1M | 444,173 | 0.6% | 1 |
| HINGE HEALTH INC | [HNGE](https://holderbook.com/stocks/HNGE/) | $6.9M | 82,860 | 0.6% | 1 |
| ARCUTIS BIOTHERAPEUTICS INC | [ARQT](https://holderbook.com/stocks/ARQT/) | $6.3M | 242,069 | 0.5% | 1 |
| INTEGRA LIFESCIENCES HLDGS C | [IART](https://holderbook.com/stocks/IART/) | $6.3M | 348,746 | 0.5% | 1 |
| ILLUMINA INC | [ILMN](https://holderbook.com/stocks/ILMN/) | $6.2M | 35,040 | 0.5% | 2 |
| MEIRAGTX HLDGS PLC | [MGTX](https://holderbook.com/stocks/MGTX/) | $6.2M | 455,286 | 0.5% | 1 |
| OCULIS HOLDING AG | [OCS](https://holderbook.com/stocks/OCS/) | $6.0M | 436,042 | 0.5% | 1 |
| NATERA INC | [NTRA](https://holderbook.com/stocks/NTRA/) | $6.0M | 22,077 | 0.5% | 2 |
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $5.8M | 43,264 | 0.5% | 3 |
| GUARDANT HEALTH INC | [GH](https://holderbook.com/stocks/GH/) | $5.5M | 36,701 | 0.5% | 1 |
| CELCUITY INC | [CELC](https://holderbook.com/stocks/CELC/) | $5.5M | 52,155 | 0.5% | 1 |
| BELITE BIO INC | [BLTE](https://holderbook.com/stocks/BLTE/) | $5.4M | 34,803 | 0.5% | 3 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $4.9M | 91,550 | 0.4% | 6 |
| ARCUS BIOSCIENCES INC | [RCUS](https://holderbook.com/stocks/RCUS/) | $4.7M | 152,129 | 0.4% | 1 |
| CHARLES RIV LABS INTL INC | [CRL](https://holderbook.com/stocks/CRL/) | $4.3M | 18,747 | 0.4% | 1 |
| ELANCO ANIMAL HEALTH INC | [ELAN](https://holderbook.com/stocks/ELAN/) | $4.2M | 172,489 | 0.4% | 1 |
| ARGENX SE | [ARGX](https://holderbook.com/stocks/ARGX/) | $4.2M | 4,482 | 0.4% | 17 |
| BIO RAD LABS INC | [BIO](https://holderbook.com/stocks/BIO/) | $4.1M | 13,995 | 0.4% | 1 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $4.1M | 46,217 | 0.4% | 1 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $3.9M | 70,971 | 0.3% | 4 |
| MIRUM PHARMACEUTICALS INC | [MIRM](https://holderbook.com/stocks/MIRM/) | $3.7M | 31,536 | 0.3% | 1 |
| CULLINAN THERAPEUTICS INC | [CGEM](https://holderbook.com/stocks/CGEM/) | $3.5M | 192,442 | 0.3% | 3 |
| COMPASS PATHWAYS PLC | [CMPS](https://holderbook.com/stocks/CMPS/) | $3.5M | 247,589 | 0.3% | 17 |
| HCA HEALTHCARE INC | [HCA](https://holderbook.com/stocks/HCA/) | $3.2M | 8,295 | 0.3% | 16 |
| CAPRICOR THERAPEUTICS INC | [CAPR](https://holderbook.com/stocks/CAPR/) | $2.9M | 122,221 | 0.3% | 2 |
| DENALI THERAPEUTICS INC | [DNLI](https://holderbook.com/stocks/DNLI/) | $2.6M | 100,966 | 0.2% | 1 |
| SYNDAX PHARMACEUTICALS INC | [SNDX](https://holderbook.com/stocks/SNDX/) | $2.6M | 118,422 | 0.2% | 4 |
| AMYLYX PHARMACEUTICALS INC | [AMLX](https://holderbook.com/stocks/AMLX/) | $2.6M | 143,700 | 0.2% | 6 |
| TARSUS PHARMACEUTICALS INC | [TARS](https://holderbook.com/stocks/TARS/) | $2.6M | 40,579 | 0.2% | 3 |
| OUTSET MED INC | [OM](https://holderbook.com/stocks/OM/) | $2.5M | 582,122 | 0.2% | 6 |
| OMADA HEALTH INC | [OMDA](https://holderbook.com/stocks/OMDA/) | $2.5M | 114,442 | 0.2% | 1 |
| ERASCA INC | [ERAS](https://holderbook.com/stocks/ERAS/) | $2.5M | 134,088 | 0.2% | 1 |
| BIOCRYST PHARMACEUTICALS INC | [BCRX](https://holderbook.com/stocks/BCRX/) | $2.1M | 207,357 | 0.2% | 1 |
| OMNICELL COM | [OMCL](https://holderbook.com/stocks/OMCL/) | $2.0M | 49,040 | 0.2% | 1 |
| CVRX INC | [CVRX](https://holderbook.com/stocks/CVRX/) | $1.9M | 369,572 | 0.2% | 1 |
| HIMS & HERS HEALTH INC | [HIMS](https://holderbook.com/stocks/HIMS/) | $1.7M | 49,454 | 0.1% | 1 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $1.7M | 62,418 | 0.1% | 3 |
| TECTONIC THERAPEUTIC INC | [TECX](https://holderbook.com/stocks/TECX/) | $1.6M | 45,631 | 0.1% | 3 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $1.2M | 26,396 | 0.1% | 10 |
| REZOLUTE INC | [RZLT](https://holderbook.com/stocks/RZLT/) | $661.9K | 127,289 | 0.1% | 5 |
| CARIBOU BIOSCIENCES INC | [CRBU](https://holderbook.com/stocks/CRBU/) | $624.2K | 354,687 | 0.1% | 20 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +24.7% | +14.8% | +9.8% | 89% |
| Q1 2026 | -5.7% | -4.6% | -1.1% | 96% |
| Q4 2025 | +20.4% | +2.4% | +18.1% | 94% |
| Q3 2025 | +7.4% | +7.8% | -0.4% | 96% |
| Q2 2025 | +1.8% | +10.5% | -8.6% | 96% |
| Q1 2025 | +2.6% | -4.6% | +7.1% | 88% |
| Q4 2024 | -11.8% | +2.1% | -13.9% | 97% |
| Q3 2024 | +3.4% | +5.4% | -2.1% | 96% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $1.2B | 96 |
| Q1 2026 | $1.1B | 79 |
| Q4 2025 | $1.0B | 77 |
| Q3 2025 | $1.3B | 70 |
| Q2 2025 | $1.2B | 56 |
| Q1 2025 | $1.4B | 65 |
| Q4 2024 | $1.6B | 78 |
| Q3 2024 | $1.8B | 74 |
| Q2 2024 | $2.0B | 77 |
| Q1 2024 | $2.1B | 84 |
| Q4 2023 | $1.7B | 63 |
| Q3 2023 | $2.1B | 71 |